On November 26, 2025, Dare Bioscience, Inc. was notified by Bayer HealthCare LLC of the termination of their license agreement, effective February 24, 2026, which was previously related to the Ovaprene development. This decision results in no future payments or support from Bayer, although the company does not expect a material impact on its ongoing Phase 3 clinical study.